Joshua Brody, Associate Professor, Division of Hematology and Oncology at Icahn School of Medicine at Mount Sinai, shared on LinkedIn:
“Innovative and important randomized trial in Nature from Lambros Tselikas and Aurélien Marabelle MD, PhD and Team Gustave Roussy: intratumoral anti-CTLA4 immunotherapy combines more safely with systemic anti-PD1 and still yields high efficacy.”
Title: Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1
Authors: Lambros Tselikas, Sandrine Susini, Matthieu Texier, Andrey Yurchenko, Emilie Routier, Mona Amini-Adle, Edi Tihic, Séverine Mouraud, François-Xavier Danlos, Samy Ammari, Thibault Raoult, Séverine Roy, Delphine Bredel, Siham Farhane, Lydie Cassard, Irma Molinaro, Alexander Eggermont, Jean-Charles Soria, Laurence Zitvogel, Christophe Massard, Angelo Paci, Thierry de Baere, Jean-Yves Scoazec, Nathalie Chaput, Sergey Nikolaev, Nicolas Meyer, Céleste Lebbé, Stéphane Dalle, Caroline Robert, Aurélien Marabelle
Read The Full Article
Other articles about Immunotherapy on OncoDaily.